Skip to content

Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation

Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01935557
Acronym
COHERE
Enrollment
296
Registered
2013-09-05
Start date
2012-12-31
Completion date
2015-12-31
Last updated
2016-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulation; Intravascular

Keywords

Continuous heparin infusion, Intermittent heparin infusion, during catheter ablation

Brief summary

Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing during the procedure is important. Randomized comparison of continuous and intermittent heparin infusion during catheter ablation of Atrial Fibrillation.

Detailed description

Intravenous heparin was used during the procedure to prevent catheter-induced thrombosis. heparin is administered during the procedure to achieve recommended activation clotting times (ACT) values, typically \>300 seconds to prevent thromboemboli during the procedure. Most of the practitioners was that ACT level should be checked at 30- to 60-minute intervals and then have injected intermittently. intermittent heparin infusion, concentration is great changed because the heparin has 30minutes half-period. researchers postulate that a constant therapeutic concentrations would be beneficial to continuous infusion than intermittent infusion.

Interventions

DRUGContinuous heparin infusion

continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.

DRUGIntermittent heparin infusion

Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.

Sponsors

Yong Seog Oh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Atrial Fibrillation, Radiofrequency catheter ablation scheduled

Exclusion criteria

* Clinical trial denied

Design outcomes

Primary

MeasureTime frame
therapeutic ACT retention rate during procedure2 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026